Wilde Deborah, Wilken Lara, Stamm Bettina, Heppner Christina, Leha Andreas, Blaschke Martina, Herrmann-Lingen Christoph, Siggelkow Heide
Clinic of Gastroenterology and Gastrointestinal Oncology University Medical Center Goettingen Goettingen Germany.
Endokrinologikum Saarbruecken Saarbruecken Germany.
JBMR Plus. 2020 Jun 5;4(7):e10368. doi: 10.1002/jbm4.10368. eCollection 2020 Jul.
In hypoparathyroidism (HypoPT), patients suffer severely from reduced quality of life. The complexity of HypoPT demands a disease-specific control instrument to characterize symptom load. We employed a newly developed disease-specific Hypoparathyroid Patient Questionnaire (the HPQ 40/28) to investigate and quantify HypoPT patients' complaints and contributing factors. In this cross-sectional, two-center study, patients with postsurgical HypoPT ( = 49) were matched for gender and age and compared with patients having undergone thyroid surgery without HypoPT ( = 39) and patients with primary hyperparathyroidism ( = 35). The HPQ 40/28 was completed when patients visited the respective center. Clinical background information, blood tests, and current medication were documented by the physician. Serum calcium lay within the reference range in 87% of HypoPT patients, serum phosphate in 95.7%, and calcium-phosphate product (CPP) in 100%. HPQ 40/28 scores for the scales "pain and cramps" (PaC), "neurovegetative symptoms" (NVS), "numbness or tingling," and "heart palpitations" were significantly elevated in comparison with control groups. Correlations between complaints and laboratory parameters could be demonstrated in the HypoPT group, with serum calcium correlating with NVS ( = 0.309, < 0.05) and serum phosphate with loss of vitality ( = 0.349, < 0.05). CPP was the main contributor to symptom load with an influence on PaC ( = 0.295, < 0.05), loss of vitality ( = 0.498, < 0.001), numbness or tingling ( = 0.328, < 0.05), and memory problems ( = 0.296, < 0.05). In conclusion, the newly developed HPQ 40/28 successfully identified and quantified symptoms typical in HypoPT patients. Using the HPQ 40/28, the CPP was identified as the predominant factor in the severity of complaints in HypoPT. © 2020 The Authors. published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
在甲状旁腺功能减退症（HypoPT）中，患者的生活质量严重下降。HypoPT的复杂性需要一种针对该疾病的控制工具来描述症状负荷。我们采用了一种新开发的针对甲状旁腺功能减退症患者的问卷（HPQ 40/28）来调查和量化HypoPT患者的症状及相关因素。在这项横断面、双中心研究中，对49例术后HypoPT患者按性别和年龄进行匹配，并与39例未患HypoPT的甲状腺手术患者以及35例原发性甲状旁腺功能亢进患者进行比较。患者在就诊各中心时完成HPQ 40/28问卷。医生记录临床背景信息、血液检查结果和当前用药情况。87%的HypoPT患者血清钙在参考范围内，95.7%的患者血清磷在参考范围内，100%的患者钙磷乘积（CPP）在参考范围内。与对照组相比，“疼痛和痉挛”（PaC）、“神经植物性症状”（NVS）、“麻木或刺痛”以及“心悸”量表的HPQ 40/28评分显著升高。在HypoPT组中可证明症状与实验室参数之间存在相关性，血清钙与NVS相关（r = 0.309，P < 0.05），血清磷与活力丧失相关（r = 0.349，P < 0.05）。CPP是症状负荷的主要影响因素，对PaC（r = 0.295，P < 0.05）、活力丧失（r = 0.498，P < 0.001）、麻木或刺痛（r = 0.328，P < 0.05）以及记忆问题（r = 0.296，P < 0.05）均有影响。总之，新开发的HPQ 40/28成功识别并量化了HypoPT患者的典型症状。使用HPQ 40/28，CPP被确定为HypoPT患者症状严重程度的主要因素。© 2020作者。由Wiley Periodicals, Inc.代表美国骨与矿物质研究学会出版。
